Work

Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357

Year: 2020

Type: article

Abstract: Cytokine-induced killer (CIK) cells have been recognized as a new type of anti-tumor effector cells. CIK cells are a mixture of T lymphocytes. Among them, CD3+ /CD56+ T cells, which are rare in uncultured peripheral blood, are the main effector cells. CIK cells can proliferate rapidly in vitro, with stronger antitumor activity, broader target tumor spectrum, and lower adverse effect than other reported antitumor effector cells. 1 Their ease of production in vitro and antitumor potential have made them suitable candidates for cell therapy regimens in solid and hematopoietic tumor treatments. 1 , 2 Our previous retrospective study showed that the median progression-free survival (PFS) and overall survival (OS) in untreated, advanced non-small-cell lung cancer (NSCLC) patients who received CIK cell immunotherapy plus chemotherapy (13 and 24 months, respectively) were significantly longer than in those who received chemotherapy alone (6 and 10 months, respectively). 2 But so far, there is no prospective, multicenter clinical study in lung cancer. Based on our previous study, we designed this randomized, multicenter, open-label trial to further evaluate the clinical efficacy of CIK cell immunotherapy plus chemotherapy in patients with advanced squamous NSCLC (ClinicalTrials.gov number, NCT01631357).

Source: Signal Transduction and Targeted Therapy

DOI: 10.1038/s41392-020-00337-x